clinical development times for biosimilars in the united states
Published 3 years ago • 48 plays • Length 3:32Download video MP4
Download video MP3
Similar videos
-
2:47
biosimilars: approval process
-
4:20
the biosimilar development process
-
7:30
generics and biosimilars
-
5:20
data requirements for biosimilars
-
8:08
biosimilar use at mayo clinic
-
6:18
fda approves of biosimilar to infliximab – ibd in the news
-
38:15
biosimilars and biologics
-
4:12
the basics of biosimilars
-
1:36:06
revised schedule m critical requirements for manufacture of biological products
-
2:51:28
increasing the efficiency of biosimilar development programs (day 2)
-
53:56
biomedical innovation 101 seminar 2: drug discovery & therapeutic development
-
1:58
fda review and approval process for biosimilar medications
-
40:51
biologics and biosimilars interchangeability: a deep dive with industry experts
-
39:51
why ibd patients should know about biosimilars
-
7:21
biologic drugs and biosimilars
-
1:33:20
wednesday, may 20, 2015: biosimilars in the u.s.: current & emerging issues
-
49:42
cultivating a vibrant u.s. market for biosimilars: a conversation with fda’s scott gottlieb - part 1
-
1:03:55
panel discussion: biologics and biosimilars - challenges and opportunities in fdd
-
1:31:11
basics of biosimilars
-
58:33
webinar: biosimilars development in autoimmune and inflammatory diseases
-
35:31
understanding biosimilars: how the availability of biosimilars will impact clinical practice
-
33:33
a conversation on biosimilars and drug development